Showcasing Company's cGMP biologics CDMO and innovative NanoAb
pipeline
JERUSALEM, March 12,
2024 /PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on
developing inflammation and immunology (I&I) biological
products and on providing CDMO services through its Scinai
Bioservices business unit, today announced that it will be
participating in partnership meetings and exhibiting its CDMO
services at the BIO-Europe Spring 2024 conference, taking place
March 18 to 20 in Barcelona.
Several members of Scinai's leadership team will be available
for discussions with:
- Prospective clients of the company's end-to-end biologics
CDMO services.
- Potential pharma partners in the field of dermatology
interested in co-advancing or in-licensing Scinai's innovative
NanoAb for local treatment of mild to moderate plaque
psoriasis – "the Botox-like solution for psoriatic patients".
- Institutional and private investors interested in SCNI's
value proposition.
All interested parties are encouraged to schedule a meeting
through the conference partnering platform or to email Scinai
at bd@scinai.com to schedule a meeting. Throughout the conference,
Scinai will also be available at exhibitor booth #119 to
showcase its CDMO services.
Scinai's CEO, Amir
Reichman, provided an overview of Scinai's assets and
plans in this brief introductory video:
https://www.youtube.com/watch?v=eWz0E_-ogSc.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(NanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical GMP manufacturing, and
pre-clinical and clinical trial design and execution services to
early stage biotech companies. Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529
| ir@scinai.com
CDMO and Partnering | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, the potential of
Scinai's NanoAb pipeline, and the expansion of the
CDMO business and the timing of human clinical trials. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of Scinai Immunotherapeutics Ltd. Risks and
uncertainties include, but are not limited to, the risk of delay
in, or Scinai's inability to conduct, its research and development
activities, including the contemplated in-vivo studies
and a clinical trial; the risk that Scinai will not remain
listed on Nasdaq; the risk that Scinai will not be successful in
expanding its CDMO business or in-license other NanoAbs; the
risk that Scinai may not be able to secure additional
capital on attractive terms, if at all; the risk that the
therapeutic and commercial potential of NanoAbs will not be met or
that Scinai will not be successful in bringing the NanoAbs towards
commercialization; the risk of a delay in the preclinical and
clinical trials data for NanoAbs, if any; the risk that our
business strategy may not be successful; the risk that the European
Investment Bank (EIB) may accelerate the financial facility under
its finance contract with Scinai; Scinai's ability to acquire
rights to additional product opportunities; Scinai's ability to
enter into collaborations on terms acceptable to Scinai or at all;
timing of receipt of regulatory approval of Scinai's manufacturing
facility in Jerusalem, if at all
or when required; the risk that the manufacturing facility will not
be able to be used for a wide variety of applications and other
vaccine and treatment technologies; and the risk that drug
development involves a lengthy and expensive process with uncertain
outcomes. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission ("SEC") on April 17, 2023, and the Company's subsequent
filings with the SEC. Scinai undertakes no obligation to revise or
update any forward-looking statement for any reason.
Logo -
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/scinai-leadership-to-attend-bio-europe-spring-2024-302086651.html
SOURCE Scinai Immunotherapeutics Ltd.